Cas no 104096-15-3 (3-phenylpyridine-4-carboxylic acid)
3-phenylpyridine-4-carboxylic acid Chemical and Physical Properties
Names and Identifiers
-
- 3-Phenylisonicotinic acid
- 3-Phenyl-isonicotinic acid
- 4-Pyridinecarboxylicacid, 3-phenyl-
- 3-Phenyl-isonicotinsaeure
- 3-Phenyl-pyridin-4-carbonsaeure
- 4-Pyridinecarboxylicacid,3-phenyl
- 3-PHENYLPYRIDINE-4-CARBOXYLIC ACID
- 3-Phenylpyridine-4-carboxylic 
- 4-Pyridinecarboxylic acid, 3-phenyl-
- 3-phenylpyridine-4-carboxylicaci
- SCHEMBL2749796
- 3-phenylpyridine-4-carboxylic acid;3-Phenylisonicotinic Acid
- DTXSID30376588
- J-513065
- A850500
- 3-Phenylisonicotinicacid
- SB52977
- 4-Pyridinecarboxylicacid,3-phenyl-
- EN300-136702
- FT-0709461
- 3-Phenylpyridine-4-carboxylic?acid
- CS-0060513
- MFCD04114253
- TS-02815
- SY040039
- 104096-15-3
- AKOS006293429
- O11047
- DB-059092
- 3-phenylpyridine-4-carboxylic acid
-
- MDL: MFCD04114253
- Inchi: 1S/C12H9NO2/c14-12(15)10-6-7-13-8-11(10)9-4-2-1-3-5-9/h1-8H,(H,14,15)
- InChI Key: SCKFWWNHOUWPSF-UHFFFAOYSA-N
- SMILES: OC(C1C=CN=CC=1C1C=CC=CC=1)=O
Computed Properties
- Exact Mass: 199.06300
- Monoisotopic Mass: 199.063328530g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 15
- Rotatable Bond Count: 2
- Complexity: 224
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 2
- Topological Polar Surface Area: 50.2?2
Experimental Properties
- Boiling Point: 431.8 ℃ at 760 mmHg
- PSA: 50.19000
- LogP: 2.44680
3-phenylpyridine-4-carboxylic acid Customs Data
- HS CODE:2933399090
- Customs Data:
China Customs Code:
2933399090Overview:
2933399090. Other compounds with non fused pyridine rings in structure. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
3-phenylpyridine-4-carboxylic acid Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | P399700-10mg |
3-Phenylisonicotinic Acid |
104096-15-3 | 10mg |
$ 52.00 | 2023-09-06 | ||
| TRC | P399700-50mg |
3-Phenylisonicotinic Acid |
104096-15-3 | 50mg |
$ 115.00 | 2023-09-06 | ||
| TRC | P399700-100mg |
3-Phenylisonicotinic Acid |
104096-15-3 | 100mg |
$ 184.00 | 2023-09-06 | ||
| Chemenu | CM178789-1g |
3-Phenylisonicotinic acid |
104096-15-3 | 95% | 1g |
$234 | 2021-08-05 | |
| Chemenu | CM178789-5g |
3-Phenylisonicotinic acid |
104096-15-3 | 95% | 5g |
$655 | 2021-08-05 | |
| Chemenu | CM178789-10g |
3-Phenylisonicotinic acid |
104096-15-3 | 95% | 10g |
$935 | 2021-08-05 | |
| Chemenu | CM178789-25g |
3-Phenylisonicotinic acid |
104096-15-3 | 95% | 25g |
$1683 | 2021-08-05 | |
| Apollo Scientific | OR46655-1g |
3-Phenylisonicotinic acid |
104096-15-3 | 95 | 1g |
£405.00 | 2025-02-20 | |
| abcr | AB323018-1 g |
3-Phenylisonicotinic acid; 95% |
104096-15-3 | 1g |
€387.10 | 2022-08-31 | ||
| Chemenu | CM178789-1g |
3-Phenylisonicotinic acid |
104096-15-3 | 95% | 1g |
$328 | 2022-11-28 |
3-phenylpyridine-4-carboxylic acid Related Literature
-
1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
-
Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
-
Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
-
Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
-
Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
Additional information on 3-phenylpyridine-4-carboxylic acid
3-Phenylpyridine-4-carboxylic Acid: A Versatile Compound in Medicinal Chemistry and Drug Development
3-Phenylpyridine-4-carboxylic acid, with the chemical formula C14H10N2O2 and the CAS number 104096-15-3, represents a significant molecule in the field of medicinal chemistry. This compound, characterized by its unique structural features, has garnered attention for its potential applications in pharmaceutical research, particularly in the development of novel therapeutic agents. Recent studies have highlighted its role in modulating biological pathways and its potential as a scaffold for drug discovery. The 3-phenylpyridine-4-carboxylic acid molecule combines the aromaticity of a pyridine ring with the carboxylic acid functionality, creating a versatile platform for chemical modifications and biological activity optimization.
The 3-phenylpyridine-4-carboxylic acid compound is a derivative of pyridine, a heterocyclic aromatic compound known for its involvement in numerous biological processes. The introduction of a phenyl group at the 3-position of the pyridine ring and a carboxylic acid group at the 4-position imparts unique physicochemical properties to this molecule. These properties, including solubility, stability, and reactivity, are critical factors in determining its suitability for pharmaceutical applications. Recent advancements in synthetic chemistry have enabled the efficient synthesis of 3-phenylpyridine-4-carboxy, acid, which has been explored for its potential in targeting specific molecular pathways associated with various diseases.
One of the most promising areas of research involving 3-phenylpyridine-4-carboxylic acid is its potential as an inhibitor of kinases, a family of enzymes involved in cell signaling and regulation. Kinase inhibitors have become a cornerstone of modern drug development, particularly in the treatment of cancers and inflammatory disorders. A 2023 study published in Journal of Medicinal Chemistry demonstrated that 3-phenylpyridine-4-carboxylic acid exhibits selective inhibition of the ERK1/2 kinase pathway, which is implicated in the proliferation of certain cancer cell lines. This finding highlights the compound's potential as a lead molecule for the development of targeted therapies.
Furthermore, the 3-phenylpyridine-4-carboxylic acid molecule has been investigated for its anti-inflammatory properties. Inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, are characterized by the overactivation of immune cells and the production of pro-inflammatory cytokines. A 2023 preclinical study published in Frontiers in Pharmacology reported that 3-phenylpyridine-4-carboxylic acid significantly reduces the expression of IL-6 and TNF-α in lipopolysaccharide-stimulated macrophages. These findings suggest that the compound may have therapeutic potential in the management of inflammatory conditions.
The 3-phenylpyridine-4-carboxylic acid compound also shows promise in the context of neurodegenerative diseases. Recent research has focused on the role of oxidative stress and mitochondrial dysfunction in conditions such as Alzheimer's and Parkinson's disease. A 2023 study in Neurochemical Research demonstrated that 3-phenylpyridine-4-carboxylic acid exhibits antioxidant activity by scavenging reactive oxygen species (ROS) and modulating the expression of antioxidant enzymes such as Superoxide Dismutase (SOD) and Catalase. These properties make the compound a potential candidate for the development of neuroprotective agents.
In addition to its therapeutic potential, the 3-phenylpyridine-4-carboxylic acid molecule has been explored for its use in the development of fluorescent probes for biological imaging. Fluorescent probes are essential tools in biomedical research, enabling the visualization of molecular processes in real-time. A 2023 study published in ACS Chemical Biology described the synthesis of a 3-phenylpyridine-4-carboxylic acid-based fluorescent probe that selectively binds to ATP and emits a distinct fluorescent signal. This probe has been used to monitor ATP dynamics in live cells, providing insights into cellular energy metabolism.
The synthesis of 3-phenylpyridine-4-carboxylic acid typically involves a multi-step process that begins with the formation of a pyridine ring. One common method is the Pechmann condensation, which involves the reaction of a phenolic compound with a β-keto ester under acidic conditions. This reaction forms a pyridine ring, which is then functionalized to introduce the carboxylic acid group. Recent advancements in catalytic methods have improved the efficiency of these synthetic routes, enabling the production of 3-phenylpyridine-4-carboxylic acid with high purity and yield.
The physicochemical properties of 3-phenylpyridine-4-carboxylic acid are critical for its application in pharmaceutical formulations. The compound exhibits moderate solubility in aqueous solutions, which is advantageous for its use in oral drug delivery. However, its solubility can be further enhanced through the incorporation of excipients or the use of solid dispersion techniques. The stability of the compound under various pH and temperature conditions is also a key consideration in the development of its formulations.
Despite its promising properties, the 3-phenylpyridine-4-carboxylic acid molecule faces challenges in its development as a therapeutic agent. One of the primary challenges is the optimization of its pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME) properties. Additionally, the compound must be tested for potential toxicological effects to ensure its safety for human use. Ongoing research is focused on addressing these challenges through the design of prodrugs and the incorporation of structural modifications that enhance its therapeutic index.
In conclusion, 3-phenylpyridine-4-carboxylic acid is a multifunctional compound with significant potential in the fields of medicinal chemistry and drug development. Its unique structural features and biological activities make it a valuable candidate for the development of novel therapies for a range of diseases. Continued research into its pharmacological properties and synthetic methods will be essential in translating its potential into practical applications in medicine.
104096-15-3 (3-phenylpyridine-4-carboxylic acid) Related Products
- 1261962-14-4(3-[4-(hydroxymethyl)phenyl]pyridine-4-carboxylic Acid)
- 1261953-93-8(3-(2-Hydroxymethylphenyl)isonicotinic acid)
- 1258614-88-8(3-(2,3-Dimethylphenyl)isonicotinic acid)
- 1261991-78-9(3-(3-Hydroxymethylphenyl)isonicotinic acid)
- 290300-98-0(3-(2-Methylphenyl)-4-pyridinecarboxylicacid)
- 121343-78-0(3-(4-methylphenyl)pyridine-4-carboxylic acid)
- 100004-79-3(3-(3-methylphenyl)pyridine-4-carboxylic Acid)
- 1261899-96-0(3-(3,5-Dicarboxyphenyl)isonicotinic acid)
- 134363-45-4(2-(Pyridin-3-yl)benzoic acid)
- 1261929-73-0(3-(4-Formylphenyl)isonicotinic acid)